Literature DB >> 9407323

Distribution of hepatitis C virus genotypes among blood donors in Taiwan.

C H Wu1, M F Lee, H S Kuo.   

Abstract

The aim of this study was to investigate the prevalence and distribution of hepatitis C virus (HCV) genotypes of blood donors in Taiwan. RNA was extracted from the serum of anti-hepatitis C virus-positive carriers and this was followed by reverse transcriptase-polymerase chain reaction (RT-PCR) using type-specific primers for the presence of HCV genotypes, 1a, 1b, 2a, 2b, 3a and 6a. Of the 604 anti-HCV-positive specimens, the PCR demonstrated that 93.0% (562/604) were positive for at least one HCV genotype. The remaining 42 specimens (7%) were HCV negative. Among the 562 HCV-positive specimens, 505 (89.8%) contained HCV 1a, 1b, 2a, 2b and 3a as the only genotype, with a prevalence of 0.4% (2/562), 60.1% (338/562), 15.5% (87/562), 11.9% (67/562), and 2.0% (11/562), respectively. No HCV genotype 6a was found. Thirty-seven specimens (6.6%) exhibited mixed infections with multiple HCV genotypes that included types 1b, 2a and 2b, while 20 (3.5%) HCV RNA-positive sera remained unclassified. These results confirm that the predominant HCV genotype in Taiwan is 1b. In addition, genotypes 1a and 3a can also be found in Taiwan at low frequency.

Entities:  

Mesh:

Year:  1997        PMID: 9407323     DOI: 10.1111/j.1440-1746.1997.tb00524.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

Review 1.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

2.  Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

Authors:  Hsien-Hong Lin; Shih-Jer Hsu; Sheng-Nan Lu; Wan-Long Chuang; Chao-Wei Hsu; Rong-Nan Chien; Sien-Sing Yang; Wei-Wen Su; Jaw-Ching Wu; Tzong-Hsi Lee; Cheng-Yuan Peng; Kuan-Chiao Tseng; Albert Qin; Yi-Wen Huang; Pei-Jer Chen
Journal:  JGH Open       Date:  2021-07-10

3.  Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.

Authors:  Hsin-Yun Sun; Chien-Yu Cheng; Chi-Ying Lin; Chia-Jui Yang; Nan-Yao Lee; Bo-Huang Liou; Hung-Jen Tang; Yuang-Meng Liu; Chun-Yuan Lee; Tun-Chieh Chen; Yi-Chia Huang; Yuan-Ti Lee; Ming-Jui Tsai; Po-Liang Lu; Hung-Chin Tsai; Ning-Chi Wang; Tung-Che Hung; Shu-Hsing Cheng; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2022-03-21       Impact factor: 5.742

4.  Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6.

Authors:  Guan-Jhou Chen; Hsin-Yun Sun; Sui-Yuan Chang; Li-Hsin Su; Yi-Ting Chen; Szu-Min Hsieh; Wan-Da Liu; Wang-Huei Sheng; Yu-Shan Huang; Kuan-Yin Lin; Yi-Ching Su; Wen-Chun Liu; Chien-Ching Hung
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.